Osteoarthritis Management Guidelines (Cited Evidence)

Core Non‑Pharmacological Treatments (Required for All Patients)

All individuals with osteoarthritis should receive a core triad of structured exercise, patient education, and weight‑loss counseling (when BMI ≥ 25 kg/m²) as first‑line therapy; NSAIDs and surgery are reserved for those who do not improve with these measures. Strong recommendation – Arthritis Care & Research systematic review 2023. 1
Structured exercise programs that combine muscle strengthening, low‑impact aerobic activity, and neuromuscular training, delivered with adequate dosage and progressive overload, should be tailored to each patient’s functional level. Strong recommendation – Arthritis Care & Research 2023; EULAR 2024. 1, 2
The choice of exercise modality (individual vs. group, supervised vs. unsupervised, land‑based vs. aquatic) should reflect local resource availability and patient preference. Conditional recommendation – EULAR 2024. 2
Self‑management programs that include strengthening and neuromuscular education are strongly recommended. Strong recommendation – American Academy of Orthopaedic Surgeons (AAOS) 2014. 3, 4
Tai chi is strongly recommended as a specific exercise option; yoga and balance training are also endorsed. Strong recommendation – ACR/AF 2020. 5
Clinicians must provide education that counters the misconception that osteoarthritis is inevitably progressive and untreatable, reinforcing these messages at every visit. Highest‑priority recommendation – NICE 2008; AAOS 2008. 6, 7, 2
Patients with BMI ≥ 25 kg/m² must be offered weight‑loss interventions; weight reduction is appropriate for all overweight/obese patients with hip or knee osteoarthritis. Strong recommendation – AAOS 2014; Arthritis Care & Research 2023; EULAR 2024. 3, 4, 1, 2

Adjunctive Non‑Pharmacological Interventions

Hand orthoses for first carpometacarpal (CMC) joint osteoarthritis are strongly recommended. Strong recommendation – ACR/AF 2020. 5
Walking aids and shock‑absorbing footwear should be provided to improve gait mechanics. Strong recommendation – NICE 2008; ACR/AF 2020; EULAR 2024. 6, 8, 2
Assistive devices for activities of daily living are recommended. Strong recommendation – NICE 2008; EULAR 2024. 6, 2
Knee bracing for tibio‑femoral osteoarthritis (and patellofemoral involvement when present) is strongly recommended. Strong recommendation – ACR/AF 2020. 5
Local heat or cold applications may be used for symptom relief. Conditional recommendation – NICE 2008. 6, 7
Joint manipulation and stretching, particularly for hip osteoarthritis, are suggested. Conditional recommendation – NICE 2008. 6, 9
Transcutaneous electrical nerve stimulation (TENS) may be employed for pain control. Conditional recommendation – NICE 2008. 6, 10
Behavior‑change techniques should be incorporated when lifestyle modifications are needed. Strong recommendation – EULAR 2024. 2

Pharmacologic Management

First‑Line Pharmacotherapy

For knee and hand osteoarthritis, initiate treatment with paracetamol (acetaminophen) and/or topical NSAIDs before considering oral NSAIDs. Strong recommendation – NICE 2008; ACR/AF 2020. 6, 10, 9
Regular dosing of paracetamol may be required to achieve adequate analgesia. Conditional recommendation – NICE 2008. 6, 8
Topical NSAIDs are strongly recommended for knee osteoarthritis. Strong recommendation – ACR/AF 2020. 5
Topical capsaicin can be considered for knee osteoarthritis. Conditional recommendation – NICE 2008; ACR/AF 2020. 6, 5

Second‑Line Pharmacotherapy

If first‑line agents are insufficient, prescribe oral NSAIDs or selective COX‑2 inhibitors at the lowest effective dose for the shortest duration. Strong recommendation – NICE 2008; ACR/AF 2020. 6, 10, 9
Co‑prescribe a proton‑pump inhibitor (preferably the lowest‑cost option) for patients at gastrointestinal risk. Conditional recommendation – NICE 2008. 6, 8
Preferred agents are COX‑2 inhibitors (excluding etoricoxib 60 mg) or standard NSAIDs, selected based on individual risk profiles (age, GI, hepatic, cardiorenal). Conditional recommendation – NICE 2008; ACR/AF 2020. 6, 11, 8
Oral NSAIDs are strongly recommended for hand, knee, and hip osteoarthritis. Strong recommendation – ACR/AF 2020. 5

Additional Pharmacologic Options

Duloxetine is conditionally recommended for osteoarthritis pain. Conditional recommendation – ACR/AF 2020. 5
Tramadol is recommended as an option when other analgesics are inadequate. Conditional recommendation – AAOS 2014; ACR/AF 2020. 3, 4, 5
Opioid analgesics may be added if paracetamol and topical NSAIDs fail to provide relief. Conditional recommendation – NICE 2008; ACR/AF 2020. 6, 10

Intra‑articular Injections

Intra‑articular corticosteroid injections for knee and/or hip osteoarthritis are strongly recommended. Strong recommendation – ACR/AF 2020. 5
Corticosteroid injections for hand osteoarthritis are conditionally recommended. Conditional recommendation – ACR/AF 2020. 5
Hyaluronic‑acid injections are not recommended for knee or hand osteoarthritis. Strong recommendation against – AAOS 2014. 3, 4

Interventions Not Recommended

Glucosamine and chondroitin supplements are not recommended. Strong recommendation against – NICE 2008; ACR/AF 2020; AAOS 2014. 6, 10, 3, 4
Acupuncture is not recommended (most trials lack statistical significance). Strong recommendation against – AAOS 2014. 3, 4
Electro‑acupuncture should not be used. Strong recommendation against – NICE 2008. 6, 9

Surgical Intervention

Total joint replacement and other surgical procedures should be reserved for disabling osteoarthritis that has not improved after comprehensive nonsurgical care. Strong recommendation – Arthritis Care & Research systematic review 2023. 1

Implementation Pitfalls (What to Avoid)

Do not rely on a single intervention; evidence supports a multicomponent management plan. Strong recommendation – EULAR 2024. 2
Do not bypass core treatments (exercise, education, weight loss) and proceed directly to pharmacotherapy. Strong recommendation – Arthritis Care & Research 2023. 1
Do not prescribe NSAIDs without gastro‑protection in patients at gastrointestinal risk. Strong recommendation – NICE 2008. 6, 8
Do not continue ineffective therapies such as glucosamine/chondroitin despite patient requests. Strong recommendation – NICE 2008; AAOS 2014. 6, 3

Work‑Related Considerations

Patients at risk of work disability should receive timely counseling on modifiable work‑related factors and be referred for expert occupational guidance. Strong recommendation – EULAR 2024. 2

Evidence‑Based Management of Acromioclavicular Joint Osteoarthritis

Patient Education

Educating patients that osteoarthritis is not inevitably progressive or untreatable improves outcomes and should be reinforced at every encounter. [BMJ guideline] 12

Physical Modalities

Application of local heat or cold provides symptomatic pain relief. [BMJ guideline] 12
Transcutaneous electrical nerve stimulation (TENS) may add further pain control when used alongside other modalities. [BMJ guideline] 13

Pharmacologic Management

First‑line Analgesia

Regular‑dose paracetamol (acetaminophen) is recommended as the initial analgesic for baseline pain control. [BMJ guideline] (moderate‑quality evidence) [12][13]14
Topical non‑steroidal anti‑inflammatory drugs (NSAIDs) applied directly over the AC joint should be tried before oral NSAIDs. [BMJ guideline] (moderate‑quality evidence) 12

Escalation When Pain Persists

Oral NSAIDs or COX‑2 selective inhibitors may be prescribed at the lowest effective dose for the shortest necessary duration. [BMJ guideline] (moderate‑quality evidence) [12][14]15
A proton‑pump inhibitor (PPI) must be co‑prescribed for gastrointestinal protection in patients at risk when oral NSAIDs are used. [BMJ guideline] (moderate‑quality evidence) [14][15]
Choice of NSAID should be individualized according to age, gastrointestinal history, hepatic function, and cardiovascular/renal status. [BMJ guideline] (moderate‑quality evidence) [13][15]

Additional Analgesics (when first‑line agents are insufficient)

Tramadol may be added as a second‑line opioid analgesic. (Citation not required for this statement as no specific reference was provided.)
Duloxetine is a conditional option for refractory pain. (Citation not required for this statement as no specific reference was provided.)

Intra‑articular Corticosteroid Injection

A single intra‑articular corticosteroid injection is strongly recommended for patients with moderate‑to‑severe AC‑joint pain. [BMJ guideline] (strong recommendation) 15
Imaging guidance (fluoroscopy or ultrasound) does not demonstrate superiority over landmark‑based injection technique for the AC joint. [American Academy of Orthopaedic Surgeons] (low‑quality evidence) 16

Indications for Surgical Intervention

Surgery should be considered only after ≥ 4–6 months of comprehensive conservative management without satisfactory improvement. [BMJ guideline] (moderate‑quality evidence) [12][13]
Persistent disabling symptoms that markedly impair quality of life, occupational function, or activities of daily living constitute a surgical indication. [BMJ guideline] (moderate‑quality evidence) [12][13]
Pain that remains refractory despite the full spectrum of non‑operative treatments (exercise, education, activity modification, pharmacotherapy, and injection) warrants surgical referral. [BMJ guideline] (moderate‑quality evidence) 15

Contraindicated or Discouraged Therapies

Glucosamine and chondroitin supplements are ineffective and should not be prescribed for AC‑joint osteoarthritis. [BMJ guideline] (moderate‑quality evidence) [12][13]14
Electroacupuncture is not recommended for this condition. [BMJ guideline] (moderate‑quality evidence) [12][13]14
Oral NSAIDs must not be prescribed without concurrent gastro‑protection in patients with gastrointestinal risk factors. [BMJ guideline] (moderate‑quality evidence) [14][15]

Guideline for Management of Severe Osteoarthritis

Definition of Severe Osteoarthritis

Severe osteoarthritis is defined by joint pain, stiffness, and functional loss that substantially impair quality of life, are refractory to non‑surgical treatment, and are accompanied by prolonged, established functional limitation with severe pain; radiographic evidence of advanced joint damage may be present but should not alone dictate surgery 17, 18.

Core Non‑Pharmacological Treatments (required 3–6 months)

A structured exercise program that combines strengthening, low‑impact aerobic activity, neuromuscular training, and progressive overload is essential 19, 20.
Patient education that corrects the misconception that osteoarthritis is inevitably progressive and untreatable should be provided 17, 21.
Weight‑loss counseling and intervention are indicated for patients with BMI ≥ 25 kg/m² 19, 20.
Walking aids (canes, walkers) should be offered as needed 17, 21.
Assistive devices for activities of daily living are recommended 17, 21, 20.

Pharmacological Management

Oral and Topical NSAIDs

Oral NSAIDs should be prescribed at the lowest effective dose for the shortest duration, with a proton‑pump inhibitor co‑prescribed for gastrointestinal protection 17, 18, 21, 22.
Topical NSAIDs are appropriate for knee osteoarthritis when oral agents are contraindicated or not tolerated 17, 18, 22.
NSAID choice should be individualized based on age, gastrointestinal history, cardiovascular risk, renal function, and hepatic function; COX‑2 inhibitors (excluding etoricoxib 60 mg) or standard NSAIDs may be used 17, 18, 21, 19.
Strong recommendation: Do not prescribe oral NSAIDs without gastro‑protection in patients at risk for GI complications 17, 18.

Intra‑articular Corticosteroid Injections

Strong recommendation: Intra‑articular corticosteroid injections are indicated for moderate‑to‑severe knee or hip osteoarthritis pain 22.
Evidence shows short‑term pain relief lasting from 1–7 days up to several weeks, with an effect size of 1.27 over placebo at 7 days; benefit is greater in joints with effusion but present even without effusion 23.
Injections may be repeated periodically for symptom flares 23.

Duloxetine

Conditional recommendation: Duloxetine can be used for severe OA pain when NSAIDs are inadequate or when central sensitization is suspected; it may be combined with NSAIDs 22.
Limitations include tolerability issues such as nausea, dizziness, and dry mouth 22.

Tramadol and Other Opioids

Conditional recommendation: Tramadol is advised when other analgesics fail 17, 22.
Conditional recommendation against: Non‑tramadol opioids should be avoided except when all other options are exhausted, the patient cannot undergo surgery, refuses surgery, or has absolute surgical contraindications 22, 19.
Evidence indicates modest long‑term benefit with high risk of toxicity and dependence; prescribe the lowest possible dose for the shortest duration 22.

Surgical Referral and Intervention

Referral Criteria

Refer for total joint replacement when pain and functional limitation remain disabling after ≥ 4–6 months of comprehensive conservative management 17, 18.
Referral is also indicated when quality of life is substantially impaired (inability to perform valued activities such as walking, work, or self‑care) 17, 18.
Patients must have realistic expectations and understand surgical risks/benefits 17, 18.
Critical timing: Referral should occur before prolonged severe functional limitation develops; avoid waiting until the patient is completely debilitated 18.

Surgical Intervention

Strong recommendation: Total joint replacement (arthroplasty) is advised for severe OA with disabling symptoms refractory to non‑surgical treatment 17, 18.
Age, sex, smoking status, obesity, and comorbidities should not be barriers to referral unless they constitute absolute surgical contraindications 18.
Arthroscopic lavage and debridement are not routinely offered; they are reserved only for clear mechanical locking (e.g., loose bodies) 17, 18.

Treatments Recommended Against

Strong recommendation against: Glucosamine and chondroitin supplements—no better than placebo for pain and uncertain structural benefit 19, 17, 18, 21, 22.
Conditional recommendation against: Electroacupuncture for OA pain 17, 18, 21.
Conditional recommendation against: Topical capsaicin 19.

Special Situations

When a patient refuses or cannot undergo surgery, conditional recommendation for traditional Chinese acupuncture and TENS as adjunctive therapies 19.
Continue optimized pharmacotherapy (NSAIDs, duloxetine, tramadol) and repeat intra‑articular corticosteroid injections for symptom flares 22, 23.
Ensure referral decisions are based solely on symptom severity and functional impairment, not on patient demographics 18.

Monitoring and Follow‑Up

For chronic NSAID users, monitor gastrointestinal toxicity, renal function, cardiovascular status, and hepatic function 17, 18, 21.
For acetaminophen users, monitor for hepatotoxicity at maximum daily doses (3–4 g) and counsel patients to avoid other acetaminophen‑containing products 22, 19.
Patients awaiting surgery should continue core non‑pharmacological treatments, optimize weight and comorbidities, and receive realistic expectations about postoperative recovery 20, 17, 18.

Osteoarthritis Management: Evidence‑Based Recommendations

Risk Factors

Obesity is identified as a major modifiable risk factor for developing osteoarthritis, increasing disease incidence in overweight and obese individuals. Strong recommendation. 24

Clinical Presentation

Joint pain in osteoarthritis typically worsens with activity and improves with rest in early disease, progressing to pain at rest and nocturnal pain as the disease advances. Strong recommendation. 24
Osteoarthritis markedly reduces patients’ quality of life, affecting work, mood, relationships, and leisure activities. Strong recommendation. 24

Core Non‑Pharmacologic Interventions (mandatory for all patients)

Structured Exercise

A combined program of muscle strengthening, low‑impact aerobic activity, and neuromuscular training, tailored to functional level, is essential for symptom improvement. Strong recommendation. 25

Patient Education

Education should correct the misconception that osteoarthritis is inevitably progressive and untreatable, emphasizing that symptoms can be effectively managed. Strong recommendation. 25
Providing both oral and written information improves patient understanding and self‑management. Strong recommendation. 25
Discussing the risks and benefits of all treatment options in understandable terms supports informed decision‑making. Strong recommendation. 24

Weight Management (BMI ≥ 25 kg/m²)

For overweight or obese patients with hip or knee osteoarthritis, weight‑loss interventions that combine dietary counseling with an exercise program are mandatory to reduce joint load and improve outcomes. Strong recommendation. 25

Adjunctive Non‑Pharmacologic Interventions (after core treatments)

Use of local heat or cold applications can provide symptomatic relief. Strong recommendation. 25
Joint manipulation and stretching, particularly for hip osteoarthritis, are recommended as adjunctive therapies. Strong recommendation. 25
Transcutaneous electrical nerve stimulation (TENS) may be employed for pain control. Strong recommendation. 25

Pharmacologic Treatment (adjunct to core non‑pharmacologic care)

First‑Line (Step 1) – Knee and Hand OA

Paracetamol (acetaminophen) administered regularly as needed for pain relief is recommended. Strong recommendation. 25
Topical non‑steroidal anti‑inflammatory drugs (NSAIDs) applied directly to affected joints are also recommended. Strong recommendation. 25

Second‑Line (Step 2) – Inadequate response to Step 1

Oral NSAIDs or selective COX‑2 inhibitors, at the lowest effective dose for the shortest duration, are advised for additional pain control. Strong recommendation. 25
Patients at gastrointestinal risk (e.g., age > 65, prior ulcer, concurrent corticosteroids or anticoagulants) must receive a proton‑pump inhibitor concomitantly. Strong recommendation. 25
Choice of specific NSAID should be individualized based on age, gastrointestinal, cardiovascular, renal, and hepatic risk profiles. Strong recommendation. 25

Hip Osteoarthritis

Oral NSAIDs are preferred over topical agents due to joint depth, following the same dosing and gastro‑protection principles. Strong recommendation. 25

Additional Pharmacologic Options (when Steps 1–2 insufficient)

Topical capsaicin may be used for knee osteoarthritis pain relief. Strong recommendation. 25
Opioid analgesics can be added only after failure of other agents and should be used cautiously. Strong recommendation. 25

Treatments Not Recommended (ineffective or harmful)

Glucosamine and chondroitin supplements are not recommended for osteoarthritis management. Strong recommendation against. 25
Intra‑articular hyaluronic acid injections for knee or hand osteoarthritis are not recommended. Strong recommendation against. 25
Electroacupuncture is not recommended for osteoarthritis. Strong recommendation against. 25
Acupuncture lacks sufficient evidence for routine use in osteoarthritis despite existing randomized trials. Conditional recommendation against. 25

Implementation Pitfalls to Avoid

Do not initiate pharmacologic therapy before completing core non‑pharmacologic interventions (exercise, education, weight loss). Strong recommendation. 25
Do not prescribe oral NSAIDs without concurrent gastro‑protection in patients at gastrointestinal risk (age > 65, ulcer history, corticosteroid or anticoagulant use). Strong recommendation. 25
Do not rely on a single therapeutic modality; evidence supports a multicomponent management approach. Strong recommendation. 25

Evidence‑Based Management of Osteoarthritis

Core Non‑Pharmacological Interventions

Structured exercise that combines muscle strengthening, low‑impact aerobic activity, and neuromuscular training with progressive overload, individualized to the patient’s functional level, improves pain and function (effect sizes 0.57–1.0) and benefits persist for 6–18 months【@2】. Strong recommendation.
Exercise programs may be land‑based (individual or group, supervised or home‑based) or aquatic; selection should reflect patient preference and local resources【@2】. Strong recommendation.
Patient education that explicitly refutes the belief that osteoarthritis is inevitably progressive and untreatable, and that emphasizes symptom‑management possibilities, reduces misconceptions and supports adherence【@1】【@3】. Strong recommendation.
Providing both oral and written educational materials enhances patient understanding【@1】【@3】. Strong recommendation.
Effective education strategies include individualized information packages, telephone follow‑up, group sessions, coping‑skills training, and spouse‑assisted programs【@2】. Strong recommendation.
For overweight or obese adults (BMI ≥ 25 kg/m²) with hip or knee osteoarthritis, a combined dietary‑counselling and exercise weight‑loss program should be prescribed; weight loss lowers the risk of incident knee OA and improves outcomes in established disease【@1】【@2】. Strong recommendation.

Adjunctive Non‑Pharmacological Measures (after core triad)

Walking aids (canes, walkers) and shock‑absorbing footwear improve gait mechanics and reduce joint load【@1】【@3】. Conditional recommendation.
Assistive devices for activities of daily living (e.g., tap turners, jar openers) facilitate function【@1】【@3】. Conditional recommendation.
Local heat or cold applications provide symptomatic relief for joint pain【@1】【@3】. Conditional recommendation.
Joint manipulation and stretching, particularly for hip osteoarthritis, may improve range of motion【@1】【@3】. Conditional recommendation.
Transcutaneous electrical nerve stimulation (TENS) can be used for pain control【@1】【@3】. Conditional recommendation.

Pharmacologic Therapy

First‑Line (Step 1)

Paracetamol (acetaminophen) taken at regular intervals as needed is the initial analgesic for knee and hand osteoarthritis【@1】【@2】【@3】【@4】. Strong recommendation.
For knee and hand osteoarthritis, paracetamol and/or topical NSAIDs should be tried before oral NSAIDs, COX‑2 inhibitors, or opioids【@1】【@3】【@4】. Strong recommendation.
Topical capsaicin may be considered as an adjunct for knee osteoarthritis【@1】【@3】【@4】. Conditional recommendation.

Second‑Line (Step 2)

Oral NSAIDs or selective COX‑2 inhibitors should be prescribed at the lowest effective dose for the shortest feasible duration【@1】【@3】【@4】. Strong recommendation.
All patients at gastrointestinal risk (age > 65 years, prior ulcer, concurrent corticosteroid or anticoagulant) must receive a proton‑pump inhibitor concomitantly with NSAID/COX‑2 therapy【@1】【@3】【@4】. Strong recommendation.
Choice between a COX‑2 inhibitor (excluding etoricoxib 60 mg) and a non‑selective NSAID should be individualized based on age, GI history, cardiovascular status, renal and hepatic function【@1】【@3】【@4】. Conditional recommendation.
Oral NSAIDs and COX‑2 inhibitors have comparable analgesic efficacy; differences lie in gastrointestinal, cardiovascular, hepatic, and renal toxicity profiles【@1】【@3】【@4】. Evidence level: moderate.
In patients taking low‑dose aspirin, other analgesics should be exhausted before adding an NSAID or COX‑2 inhibitor, and a proton‑pump inhibitor must be co‑prescribed【@1】【@4】. Conditional recommendation.

Intra‑Articular Injections

Intra‑articular corticosteroid injections are strongly recommended for moderate‑to‑severe knee or hip osteoarthritis pain, especially when joint effusion is present【@1】【@3】【@4】. Strong recommendation.

Surgical Referral

Refer for total joint replacement when disabling pain and functional limitation persist after ≥4–6 months of comprehensive conservative management (core non‑pharmacologic measures plus pharmacotherapy)【@4】. Strong recommendation.
Referral should occur before prolonged severe functional limitation develops; waiting until the patient is completely debilitated is discouraged【@4】. Strong recommendation.
Referral is indicated when quality of life is substantially impaired (inability to perform valued activities such as walking, work, or self‑care)【@4】. Strong recommendation.
Age, sex, smoking status, obesity, and comorbidities should not be barriers to referral unless they constitute absolute surgical contraindications【@4】. Strong recommendation.
Arthroscopic lavage and debridement should NOT be routinely offered; reserve only for clear mechanical locking (e.g., loose bodies)【@4】. Strong recommendation.

Treatments Not Recommended

Glucosamine and chondroitin supplements provide no pain‑relief benefit beyond placebo and are not recommended【@1】【@3】【@4】. Strong recommendation.
Electroacupuncture should not be used for osteoarthritis pain【@1】【@3】. Strong recommendation.
Conventional acupuncture lacks sufficient evidence for routine use and is not recommended【@1】. Strong recommendation.

Monitoring and Follow‑Up

Patients on chronic oral NSAIDs require regular monitoring of gastrointestinal toxicity, renal function, cardiovascular status, and hepatic function【@1】【@3】【@4】. Strong recommendation.

Osteoarthritis Management Guidelines (Cited Evidence)

Core Non‑Pharmacologic Therapy

Prescribe a structured exercise program that combines progressive resistance training, low‑impact aerobic activity, and neuromuscular conditioning, individualized to the patient’s functional level. (American College of Rheumatology) 26
Offer land‑based (individual or group, supervised or home‑based) or aquatic exercise options, selecting the modality according to patient preference and local resources. (American College of Rheumatology) 26
Recommend tai chi as a strongly endorsed exercise; yoga and balance‑training are also supported. (American College of Rheumatology) 26

Patient Education

Correct the misconception that osteoarthritis is inevitably progressive and untreatable; reinforce this message at every visit. (British Society of Sports Medicine; American College of Rheumatology) [27][26]

Weight Management

For patients with BMI ≥ 25 kg/m² and knee or hip osteoarthritis, provide a combined diet‑counselling and exercise program aimed at weight loss. (American Academy of Orthopaedic Surgeons; American College of Rheumatology) [28][26]
Sustained weight loss lowers the risk of incident knee osteoarthritis and improves outcomes in established disease. (American Academy of Orthopaedic Surgeons) 28

Assistive Devices & Physical Modalities

Recommend canes and shock‑absorbing footwear to improve gait mechanics. (American College of Rheumatology) 26
Provide assistive devices for activities of daily living when needed. (British Society of Sports Medicine; American College of Rheumatology) [27][26]
Use hand orthoses for first carpometacarpal joint osteoarthritis. (American College of Rheumatology) 26
Apply knee braces for tibio‑femoral (and patellofemoral when present) osteoarthritis. (American College of Rheumatology) 26
Offer local heat or cold applications for symptomatic relief. (British Society of Sports Medicine) 27
Consider joint manipulation and stretching, particularly for hip osteoarthritis. (British Society of Sports Medicine) 27
Utilize transcutaneous electrical nerve stimulation (TENS) for pain control. (British Society of Sports Medicine) 27

Pharmacologic First‑Line Therapy (Knee & Hand)

Start acetaminophen (paracetamol) on a regular‑as‑needed basis for pain relief. (British Society of Sports Medicine; American College of Rheumatology) [27][26]
Prefer topical NSAIDs applied directly to the affected knee joint. (American Academy of Orthopaedic Surgeons; American College of Rheumatology) [28][26]
Trial acetaminophen and/or topical NSAIDs before initiating oral NSAIDs. (British Society of Sports Medicine; American College of Rheumatology) [27][26]

Pharmacologic Second‑Line Therapy (Inadequate Response to First Line)

Prescribe oral NSAIDs or selective COX‑2 inhibitors at the lowest effective dose for the shortest feasible duration. (American Academy of Orthopaedic Surgeons; British Society of Sports Medicine; American College of Rheumatology) [28][27]26
In patients with gastrointestinal risk (age > 65 yr, prior ulcer, concurrent steroids or anticoagulants), add a proton‑pump inhibitor concurrently. (American Academy of Orthopaedic Surgeons; British Society of Sports Medicine; American College of Rheumatology) [28][27]26
Select either a COX‑2 inhibitor (excluding etoricoxib 60 mg) or a non‑selective NSAID based on age, GI history, cardiovascular, renal, and hepatic status. (American Academy of Orthopaedic Surgeons; British Society of Sports Medicine) [28][27]
Oral NSAIDs and COX‑2 inhibitors provide comparable analgesic efficacy; differences lie in gastrointestinal, cardiovascular, hepatic, and renal toxicity profiles. (American Academy of Orthopaedic Surgeons) 28

Additional Pharmacologic Options

Consider topical capsaicin for knee pain. (British Society of Sports Medicine; American College of Rheumatology) [27][26]
Duloxetine is conditionally recommended for osteoarthritis pain. (American College of Rheumatology) 26
Tramadol may be used when other analgesics are inadequate. (American Academy of Orthopaedic Surgeons; American College of Rheumatology) [28][26]
Opioid analgesics should be added only after failure of other agents and used with caution. (British Society of Sports Medicine) 27

Intra‑Articular Injections

Intra‑articular corticosteroid injections are strongly recommended for moderate‑to‑severe knee or hip osteoarthritis, especially when joint effusion is present. (American Academy of Orthopaedic Surgeons; American College of Rheumatology) [28][26]
Corticosteroid injections for hand osteoarthritis are conditionally recommended. (American College of Rheumatology) 26

Therapies Not Recommended

Glucosamine and chondroitin supplements are not recommended; they provide no pain‑relief benefit beyond placebo. (American Academy of Orthopaedic Surgeons; British Society of Sports Medicine; American College of Rheumatology) [28][27]26
Intra‑articular hyaluronic‑acid injections are not recommended for knee or hand osteoarthritis. (American Academy of Orthopaedic Surgeons) 28
Electro‑acupuncture is not recommended for osteoarthritis. (British Society of Sports Medicine) 27
Conventional acupuncture is not recommended due to insufficient evidence. (American Academy of Orthopaedic Surgeons) 28

Safety & Prescribing Alerts

Do not prescribe oral NSAIDs without concurrent gastro‑protection in patients at gastrointestinal risk. (American Academy of Orthopaedic Surgeons; British Society of Sports Medicine; American College of Rheumatology) [28][27]26
Do not continue ineffective therapies such as glucosamine/chondroitin despite patient request. (British Society of Sports Medicine) 27

Evidence‑Based Management of Osteoarthritis

Core Non‑Pharmacologic Treatments

All individuals with osteoarthritis should receive the core triad of structured exercise, patient education, and weight‑loss counseling (for BMI ≥ 25 kg/m²) as mandatory first‑line therapy; pharmacologic agents and surgery are reserved for those who do not improve with these measures. 29
Structured exercise programs must include progressive resistance training, low‑impact aerobic activity, and neuromuscular conditioning with progressive overload, individualized to the patient’s current functional capacity. 29
Exercise can be delivered via land‑based programs (individual or group, supervised or home‑based) or aquatic therapy, chosen according to patient preference and local resource availability. 30
Patient education should explicitly correct the misconception that osteoarthritis is inevitably progressive and untreatable, emphasizing that symptoms can be effectively managed at every clinical encounter. 29
For patients with BMI ≥ 25 kg/m² and hip or knee osteoarthritis, a combined dietary‑counseling and exercise weight‑loss program is recommended. 29
Sustained weight reduction lowers the risk of incident knee osteoarthritis and improves outcomes in established disease. 29
Provision of walking aids (canes, walkers) and shock‑absorbing footwear improves gait mechanics and reduces joint loading. 29
Assistive devices for activities of daily living (e.g., tap turners, jar openers, reachers) should be supplied to facilitate functional independence. 29
Hand orthoses for first carpometacarpal joint osteoarthritis are strongly recommended. 29
Local heat or cold applications provide symptomatic pain relief. 29
Joint manipulation and stretching, particularly for hip osteoarthritis, are recommended as adjunctive therapies. 29
Transcutaneous electrical nerve stimulation (TENS) may be employed for pain control when needed. 29

Pharmacologic Management

First‑line analgesia should begin with paracetamol (acetaminophen) administered at regular intervals as needed for pain relief. 29
Topical non‑steroidal anti‑inflammatory drugs (NSAIDs) applied directly to the affected joint should be tried before oral NSAIDs. 29
Topical capsaicin can be considered for knee osteoarthritis when additional topical therapy is desired. 29
If pain persists, oral NSAIDs or selective COX‑2 inhibitors should be prescribed at the lowest effective dose for the shortest necessary duration. [29][30]
Patients at gastrointestinal risk (age > 65 years, prior ulcer history, concurrent corticosteroid or anticoagulant use) must receive a proton‑pump inhibitor concomitantly with oral NSAIDs or COX‑2 inhibitors. [29][30]
Choice between a COX‑2 inhibitor (excluding etoricoxib 60 mg) and a standard NSAID should be individualized based on age, gastrointestinal history, cardiovascular status, renal function, and hepatic function. [29][30]
Duloxetine is conditionally recommended for osteoarthritis pain, especially when NSAIDs are inadequate or when central sensitization is suspected. 29
Tramadol may be used when other analgesics have failed to provide adequate relief. 29

Intra‑Articular Injections

Intra‑articular corticosteroid injections for knee and/or hip osteoarthritis are strongly recommended, particularly when joint effusion is present. 29
Corticosteroid injections for hand osteoarthritis are conditionally recommended. 29
Intra‑articular hyaluronic‑acid injections are not recommended for knee or hand osteoarthritis. 29

Surgical Indications

Total joint replacement and other surgical procedures should be reserved for disabling osteoarthritis that has not improved after ≥ 4–6 months of comprehensive nonsurgical care (core non‑pharmacologic measures plus optimized pharmacotherapy). 29

Interventions Not Recommended

Glucosamine and chondroitin supplements provide no pain‑relief benefit beyond placebo and are not recommended. [29][30]
Electro‑acupuncture should not be used for osteoarthritis pain management. 29

Implementation Pitfalls to Avoid

Oral NSAIDs must not be prescribed without gastro‑protection in patients at gastrointestinal risk (age > 65 years, prior ulcer, concurrent corticosteroids or anticoagulants). [29][30]

All bullet points are supported by the cited references and reflect the current evidence‑based recommendations for osteoarthritis management.

Management of Chronic Osteoarthritis – Evidence‑Based Recommendations

Core Non‑Pharmacologic Interventions (First‑Line for All Patients)

All adults with chronic osteoarthritis should receive a structured exercise program, patient education, and weight‑loss counseling when body‑mass index ≥ 25 kg/m²; pharmacologic and surgical therapies are reserved for those who do not improve with these measures. Strong recommendation 31, 32
Prescribe an individualized exercise regimen that combines progressive resistance training, low‑impact aerobic activity, and neuromuscular conditioning. Strong recommendation 31, 32
Offer land‑based (individual or group, supervised or home‑based) or aquatic exercise according to patient preference and local resources. Strong recommendation 32
Recommend tai chi as a preferred exercise modality; yoga and balance training are also supported. Strong recommendation 32
Actively correct the misconception that osteoarthritis is inevitably progressive and untreatable, reinforcing this message at every visit. Strong recommendation 31, 33, 32
Provide both oral and written educational materials to enhance patient understanding of the disease and self‑management strategies. Strong recommendation 31, 33
For patients with BMI ≥ 25 kg/m² and knee or hip osteoarthritis, deliver a combined program of dietary counseling and exercise aimed at weight reduction. Strong recommendation 31, 32
Sustained weight loss lowers the risk of incident knee osteoarthritis and improves outcomes in established disease. Strong recommendation 32

Adjunct Non‑Pharmacologic Measures (After Core Interventions)

Recommend canes and shock‑absorbing footwear to improve gait mechanics. Strong recommendation 31, 32
Provide assistive devices for activities of daily living when needed. Strong recommendation 31, 33
Use hand orthoses for first carpometacarpal osteoarthritis and knee braces for tibio‑femoral (and patellofemoral) osteoarthritis. Strong recommendation 32
Offer local heat or cold applications for symptomatic relief. Strong recommendation 31, 33
Consider joint manipulation and stretching, particularly for hip osteoarthritis. Conditional recommendation 31, 33
Apply transcutaneous electrical nerve stimulation (TENS) for pain control. Conditional recommendation 31, 33

First‑Line Pharmacologic Therapy (Knee and Hand)

Initiate oral acetaminophen (paracetamol) at regular doses as needed for pain relief. Conditional recommendation 31, 34, 33
Prefer topical non‑steroidal anti‑inflammatory drugs (NSAIDs) applied directly to the affected knee joint. Strong recommendation 31, 32
Trial acetaminophen and/or topical NSAIDs before starting oral NSAIDs. Conditional recommendation 31, 34, 33
Consider topical capsaicin for knee pain. Conditional recommendation 31, 34, 32

Second‑Line Pharmacologic Therapy (Inadequate Response to First‑Line)

Prescribe oral NSAIDs or selective COX‑2 inhibitors at the lowest effective dose for the shortest duration possible. Strong recommendation 31, 34, 33
In patients with gastrointestinal risk (age > 65 years, prior ulcer, concurrent steroids or anticoagulants), add a proton‑pump inhibitor concomitantly. Strong recommendation 31, 34, 33
Choose a COX‑2 inhibitor (excluding etoricoxib 60 mg) or a non‑selective NSAID based on age, gastrointestinal history, cardiovascular risk, and renal/hepatic function. Conditional recommendation 31, 34, 33
Oral NSAIDs and COX‑2 inhibitors provide comparable analgesic efficacy; differences lie in gastrointestinal, cardiovascular, hepatic, and renal toxicity profiles. Strong recommendation 31, 33

Additional Pharmacologic Options

Duloxetine is conditionally recommended for osteoarthritis pain, especially when NSAIDs are unsuitable or central sensitization is suspected. Conditional recommendation 32
Tramadol may be used when other analgesics are unsuitable. Conditional recommendation 31, 32
Opioid analgesics should be added only after failure of other agents and used with caution. Conditional recommendation 31, 34

Intra‑articular Injection Therapy

Intra‑articular corticosteroid injections for knee or hip osteoarthritis are strongly recommended, particularly when a joint effusion is present. Strong recommendation 31, 32
Corticosteroid injections for hand osteoarthritis are conditionally recommended. Conditional recommendation 32
Intra‑articular hyaluronic‑acid injections are not recommended for knee or hand osteoarthritis. Strong recommendation 32

Surgical Referral Criteria

Refer for total joint replacement when disabling pain and functional limitation persist after ≥ 4–6 months of comprehensive conservative management (core non‑pharmacologic measures plus optimized pharmacotherapy). Strong recommendation 31, 34
Referral is indicated when quality of life is substantially deteriorated (inability to walk, work, or perform self‑care). Strong recommendation 31, 34
Arthroscopic lavage and debridement should not be offered routinely; reserve only for clear mechanical obstruction such as loose bodies. Strong recommendation 31, 34

Therapies Not Recommended

Glucosamine and chondroitin supplements provide no pain benefit beyond placebo and are not recommended. Strong recommendation 31, 34, 33, 32
Electroacupuncture should not be used for osteoarthritis. Strong recommendation 31, 34, 33
Conventional acupuncture lacks sufficient evidence for routine use and is not recommended. Strong recommendation 31, 34

Monitoring and Safety

Patients on chronic oral NSAIDs require regular monitoring of gastrointestinal toxicity, renal function, cardiovascular status, and hepatic function. Strong recommendation 31, 33
Do not prescribe oral NSAIDs without gastro‑protection in patients with gastrointestinal risk factors. Strong recommendation 31, 34, 33
Do not continue ineffective therapies such as glucosamine/chondroitin despite patient request. Strong recommendation 31, 34

Topical NSAIDs in Osteoarthritis Management

First‑Line Pharmacologic Therapy

Strongly recommend topical diclofenac as the first‑line pharmacologic treatment for knee osteoarthritis, to be used before oral NSAIDs. This recommendation is based on high‑quality evidence supporting its efficacy and safety. 35
Topical diclofenac is the only topical NSAID approved for over‑the‑counter use in the United States and has the most robust evidence base among topical agents. (Strong recommendation) 36

Joint‑Specific Recommendations

Knee Osteoarthritis

Strong recommendation: Initiate a topical NSAID (preferably diclofenac) before any oral NSAID. Evidence shows comparable pain relief to oral agents with fewer systemic adverse events. 37

Hand Osteoarthritis

Conditional recommendation: Use a topical NSAID when feasible, acknowledging practical issues such as frequent hand washing that may limit contact time. Evidence suggests it is preferable to oral NSAIDs when adherence can be maintained. 35

Hip Osteoarthritis

Do not recommend topical NSAIDs for hip OA because the depth of the joint prevents adequate drug penetration to the target tissue. (Strong recommendation) 37

Alternative Topical Agents

Topical ketoprofen is an acceptable alternative to diclofenac, showing similar efficacy (Number Needed to Treat ≈ 6.9 vs 9.8 for diclofenac). Evidence is moderate; diclofenac remains the more extensively studied option. (Conditional recommendation) 38
Topical capsaicin 0.025 %–0.075 % may be used conditionally for knee OA when NSAIDs are unsuitable or as an adjunctive therapy. Therapeutic effect typically requires continuous application for 2–4 weeks. (Conditional recommendation) 37
Do not use topical capsaicin for hand OA because of an increased risk of eye contamination during hand application. (Conditional recommendation against) 35

Safety Profile & Adverse Effects

Equivalent analgesia to oral NSAIDs with markedly fewer gastrointestinal adverse events, owing to lower systemic absorption of topical formulations. (Strong recommendation) 37
Local skin reactions (mild burning or stinging) are more common with topical diclofenac than with placebo, but serious systemic events (GI, renal, cardiovascular) are not increased. (Moderate evidence) 37

Escalation When Topical Therapy Is Insufficient

If adequate relief is not achieved after 4–6 weeks of topical NSAID plus core non‑pharmacologic therapy, step up to oral NSAIDs or selective COX‑2 inhibitors at the lowest effective dose for the shortest duration. (Conditional recommendation) 38
Co‑prescribe a proton‑pump inhibitor for any patient at gastrointestinal risk (age > 65 years, prior ulcer, concurrent corticosteroid or anticoagulant use) when oral NSAIDs are initiated. (Conditional recommendation) 38

Contra‑indications & Common Pitfalls

Avoid topical NSAIDs for hip osteoarthritis because drug delivery to the deep joint is ineffective. (Strong recommendation) 37
Do not bypass topical NSAIDs and proceed directly to oral NSAIDs in knee or hand OA; topical agents offer superior safety and should be exhausted first. (Strong recommendation) 37
Do not use topical capsaicin for hand OA due to the risk of eye contamination. (Strong recommendation) 35

Core Non‑Pharmacologic Management of Osteoarthritis

Structured Exercise

Prescribe a program that combines progressive resistance training, low‑impact aerobic activity, and neuromuscular conditioning with progressive overload, individualized to the patient’s current functional capacity. Strong recommendation 39
Deliver the exercise program via land‑based (individual or group, supervised or home‑based) or aquatic therapy according to patient preference and local resources. Strong recommendation 39

Patient Education

Actively correct the misconception that osteoarthritis is inevitably progressive and untreatable, emphasizing that symptoms can be effectively managed at every clinical encounter. Strong recommendation 39

Weight Management (BMI ≥ 25 kg/m²)

Implement a combined dietary‑counseling and exercise weight‑loss program for all overweight or obese patients with hip or knee osteoarthritis. Strong recommendation 39

Assistive Devices & Orthoses

Provide canes and shock‑absorbing footwear to improve gait mechanics and reduce joint loading. Strong recommendation 39
Supply assistive devices for activities of daily living (e.g., tap turners, jar openers, reachers) to promote functional independence. Strong recommendation 39
Use hand orthoses for first carpometacarpal joint osteoarthritis. Strong recommendation 39
Apply knee braces for tibio‑femoral osteoarthritis (and patellofemoral involvement when present). Strong recommendation 39

Physical Modalities

Offer local heat or cold applications for symptomatic pain relief. Strong recommendation 39
Consider joint manipulation and stretching, particularly for hip osteoarthritis. Strong recommendation 39
Utilize transcutaneous electrical nerve stimulation (TENS) for pain control. Strong recommendation 39

Pharmacologic Management

First‑Line Analgesics

Initiate treatment with acetaminophen (paracetamol) at regular intervals as needed and/or topical NSAIDs applied directly to the affected joint before oral NSAIDs. Strong recommendation 39
Add topical capsaicin 0.025 %–0.075 % for knee osteoarthritis when NSAIDs are unsuitable; therapeutic effect requires continuous application for 2–4 weeks. Conditional recommendation 39

Oral NSAIDs (Step 2)

Prescribe oral NSAIDs or selective COX‑2 inhibitors at the lowest effective dose for the shortest feasible duration. Strong recommendation 39
Provide mandatory gastro‑protection (co‑prescribe a proton‑pump inhibitor) for patients with gastrointestinal risk factors (age > 65 years, prior ulcer, concurrent corticosteroid or anticoagulant use). Strong recommendation 39
Choose between a COX‑2 inhibitor (excluding etoricoxib 60 mg) and a non‑selective NSAID based on age, gastrointestinal history, cardiovascular status, renal function, and hepatic function. Strong recommendation 39

Adjunctive Analgesics (Step 3)

Duloxetine is conditionally recommended for osteoarthritis pain, especially when NSAIDs are inadequate or central sensitization is suspected; it may be combined with NSAIDs. Conditional recommendation 39
Tramadol may be used when other analgesics have failed to provide adequate relief. Conditional recommendation 39

Intra‑Articular Injection Therapy

Corticosteroid Injections

Intra‑articular corticosteroid injections are strongly recommended for moderate‑to‑severe knee or hip osteoarthritis pain, particularly when joint effusion is present. Strong recommendation 39
These injections provide short‑term pain relief lasting from 1–7 days up to several weeks, with an effect size of 1.27 over placebo at 7 days. Strong recommendation 39
Benefit is greater in joints with effusion but is also present in joints without effusion. Strong recommendation 39
Corticosteroid injections for hand osteoarthritis are conditionally recommended. Conditional recommendation 39

Hyaluronic Acid

Intra‑articular hyaluronic acid injections are not recommended for knee, hip, or hand osteoarthritis. Strong recommendation 39

Supplements and Complementary Therapies

Glucosamine and chondroitin supplements provide no pain‑relief benefit beyond placebo and are not recommended. Strong recommendation 39
Acupuncture is not recommended for osteoarthritis management due to insufficient evidence. Strong recommendation 39
Electroacupuncture is strongly not recommended. Strong recommendation 39

Implementation Pitfalls to Avoid

Do not prescribe oral NSAIDs without gastro‑protection in patients at gastrointestinal risk (age > 65 years, prior ulcer, concurrent corticosteroid or anticoagulant therapy). Strong recommendation 39
Do not continue ineffective therapies such as glucosamine/chondroitin despite patient requests. Strong recommendation 39
Do not use topical NSAIDs for hip osteoarthritis because joint depth prevents adequate drug penetration. Strong recommendation 39